Abnormal Uterine Bleeding Clinical Trial
Official title:
Randomized Control Trial Investigating for Prophylactic Tranexamic Acid Use at Time of Minimally Invasive Myomectomies
This is a Double-blinded randomized placebo-controlled trial based at Eastern Virginia Medical School. Subjects who are identified in clinic having menorrhagia or abnormal Uterine bleeding (AUB) due to uterine fibroids and meet inclusion criteria based on the ultrasound (US) or Magnetic Resonance Imaging (MRI), aged 18-45 undergoing laparoscopic or Robotic assisted myomectomies. A total of 50 women in each arm of the study with symptomatic fibroids. Patients will be randomized to receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline (intervention group) versus an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2024 |
Est. primary completion date | July 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Undergoing laparoscopic myomectomy - At least one fibroid greater than or equal to 6 cm - Any intramural or broad ligament fibroid greater than or equal to 4 cm - At least 3 total fibroids based on preoperative imaging Exclusion Criteria: - Severe existing medical complications involving the heart, liver, or kidney - Moderate to severe renal impairment (serum creatinine > 1.4) - Blood clotting abnormalities - Known Allergies to tranexamic acid - Known Contraindications to Minimally invasive myomectomies - If you are pregnant - History of a prior blood clot in the lung arm or leg, known as pulmonary embolism or deep vein thrombosis - Any active blood clots, clotting disease, pulmonary embolism, cerebral thrombosis, estrogen use, renal impairment, elevated creatinine level - History of a stroke or mini-strokes - Concurrent oral contraceptive use - Contraindications to receiving Tranexamic acid - In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity - In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients. - In patients with active intravascular clotting. - In patients with hypersensitivity to tranexamic acid or any of the ingredients |
Country | Name | City | State |
---|---|---|---|
United States | EasternVMC | Norfolk | Virginia |
Lead Sponsor | Collaborator |
---|---|
Eastern Virginia Medical School |
United States,
Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD001886. doi: 10.1002/14651858.CD001886.pub3. — View Citation
Hickman LC, Kotlyar A, Shue S, Falcone T. Hemostatic Techniques for Myomectomy: An Evidence-Based Approach. J Minim Invasive Gynecol. 2016 May-Jun;23(4):497-504. doi: 10.1016/j.jmig.2016.01.026. Epub 2016 Mar 9. Erratum In: J Minim Invasive Gynecol. 2019 Feb;26(2):373. — View Citation
Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2014 Aug 15;2014(8):CD005355. doi: 10.1002/14651858.CD005355.pub5. — View Citation
Lam SJ, Best S, Kumar S. The impact of fibroid characteristics on pregnancy outcome. Am J Obstet Gynecol. 2014 Oct;211(4):395.e1-5. doi: 10.1016/j.ajog.2014.03.066. Epub 2014 Apr 3. — View Citation
Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, Silliman CC, Banerjee A. Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid. J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S65-9. doi: 10.1097/TA.0000000000000634. — View Citation
Ngichabe S, Obura T, Stones W. Intravenous tranexamic acid as an adjunct haemostat to ornipressin during open myomectomy. A randomized double blind placebo controlled trial. Ann Surg Innov Res. 2015 Oct 31;9:10. doi: 10.1186/s13022-015-0017-y. eCollection 2015. — View Citation
Opoku-Anane J, Vargas MV, Moawad G, Cherie M, Robinson JK. Use of Intravenous Tranexamic Acid During Myomectomy: A Randomized Double-Blind Placebo Controlled Trial. J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S197. doi: 10.1016/j.jmig.2015.08.715. Epub 2015 Oct 15. No abstract available. — View Citation
Parker WH. Uterine myomas: management. Fertil Steril. 2007 Aug;88(2):255-71. doi: 10.1016/j.fertnstert.2007.06.044. Epub 2007 Jul 20. — View Citation
Topsoee MF, Settnes A, Ottesen B, Bergholt T. A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery. Int J Gynaecol Obstet. 2017 Feb;136(2):120-127. doi: 10.1002/ijgo.12047. Epub 2016 Dec 9. — View Citation
WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2017. Available from http://www.ncbi.nlm.nih.gov/books/NBK493081/ — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimated blood loss | Estimated blood loss at time of procedure completion; using volume of cannister and weight of lap sponges | Duration of procedure up to 420 minutes | |
Primary | Calculated blood loss | Calculated Blood loss, using pre-operative hematocrit, postoperative hematocrit and estimated blood volume x Body Mass Index | From post operative day 0 until postoperative day 1 | |
Primary | Number of blood products received | Number of blood products received during admission that is directly due to blood loss at time of procedure | Duration of hospital stay up to two days | |
Secondary | Duration of surgery | Start time of procedure until end time of procedure | Duration of surgery up to 420 minutes | |
Secondary | Length of hospital stay | Recorded in days | Duration of stay in hospital, up to two days | |
Secondary | Number of fibroids removed | Total number of fibroids removed during procedure | Duration of surgery, up to 420 minutes | |
Secondary | Fibroid type | type of fibroid per FIGO classification | through completion of study average 8 weeks | |
Secondary | Weight of fibroids removed | total weight of fibroids removed | duration of surgery up to 420 minutes | |
Secondary | Pain index | Pain index score on postoperative day 1 and 14 Score of 0-10 0 = no pain, 10 = significant amount of pain | duration of hospital stay, up to two days | |
Secondary | Incidence of postoperative complication | Immediate postoperative complication:
Hemorrhage Infection Fever Deep vein thrombosis Hysterectomy Re-exploration Hospital readmission |
Duration of hospital stay , up to two days | |
Secondary | Questionnaire for incidence of mild side effect of medication | Reported mild effective of medication of post operative day 1 | only on postoperative day 1 , one day | |
Secondary | Questionnaire for incidence of serious side effect of medication | Reported serious side effect of medication on post operative day 1 | Only on postoperative day 1, one day | |
Secondary | tPA receptor | Percentage of tPA receptor located in fibroid and myometrium | From time of randomization until postoperative visit, four weeks | |
Secondary | PAI-1 receptor | Percentage of PAI-1receptor located in fibroid and myometrium | From time of randomization until postoeprative visit, four weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06067217 -
Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users
|
N/A | |
Completed |
NCT03638856 -
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
|
N/A | |
Recruiting |
NCT04172272 -
The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures
|
N/A | |
Completed |
NCT01908738 -
Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy
|
N/A | |
Not yet recruiting |
NCT06050161 -
Evaluating Artisential Laparoscopic Instruments in Gynecologic Surgery
|
N/A | |
Completed |
NCT04381416 -
Study to Assess the Safety and Efficacy of the IUB SEADâ„¢ Device
|
N/A | |
Recruiting |
NCT06193590 -
Suction Cervical Stabilizer Compared to Standard Tenaculum for Intrauterine Procedures
|
N/A | |
Completed |
NCT02192606 -
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?
|
N/A | |
Completed |
NCT03697733 -
Comparison Efficiency of Oral Etoricoxib Versus Intravenous Fentanyl on Post Operative Pain in Curettage Under TIVA
|
N/A | |
Completed |
NCT01721304 -
Decisionmaking for Abnormal Uterine Bleeding (AUB)
|
N/A | |
Completed |
NCT05406960 -
Therapeutic Effect of Herbal Infusion on Menometrorrhagia
|
N/A | |
Recruiting |
NCT06024109 -
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
|
||
Recruiting |
NCT06369012 -
Management of Abnormal Uterine Bleeding
|
N/A | |
Completed |
NCT06397898 -
NOVasure EXpierences (NOVEX)
|
N/A | |
Recruiting |
NCT05922657 -
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
|
||
Not yet recruiting |
NCT06398145 -
D-chiro-inositol and AUB
|
Phase 2 | |
Terminated |
NCT04475497 -
Role of Blood Management in Perioperative Outcomes
|
N/A | |
Recruiting |
NCT05062551 -
Effectiveness of Three Steps Hysteroscopic Repair of Post Caesarean Isthmocele in Patients With Post Menstrual Spotting
|
N/A | |
Terminated |
NCT05227456 -
Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study
|
Phase 2 | |
Active, not recruiting |
NCT05299801 -
DAta MIning to Evaluate Novasure Treatment
|